Early-Stage Prostate Cancer - a New Way to Determine if It's Aggressive?
Posted Feb 07 2011 12:00am
Determining how aggressive a newly diagnosed early-stage prostate cancer might be, until now, has been the Holy Grail of prostate cancer science. This beats the reported 75% accuracy reported until now.
For that reason I was delighted to read a recent announcement that Dana Farber researchers have discovered 4 genetic markers that can determine with 92% accuracy how aggressive a patient's prostate cancer tumor is when diagnosed early. For more about this see the February 5, 2011 edition of Smart About Health (/
Quite incredibly this discovery of how aggressive an early-stage prostate cacner might become, far exceeds reported 75% accuracy (some say up to 70%) reported until now.
This far-reaching, upbeat conclusion can be considered valid and reliable, providing it's based on the randomized selection of a large number of patients studied prospectively and "longitudenally," meaning, over 10-15 years, and, - of course, if the study has been successfully duplicated by other researchers. If that's the case, this is one of the major turning points in modern science! I say that because prostate cancer, like breast cancer, is the most prevalent non-skin cancer.
Subject to getting the full report, this news greatly increases the likelihood that active surveillance will become the gold standard for the vast majority of newly diagnosed prostate cancer patients. After all, some 80% of prostate cancer diagnoses occur when men's prostate cancers are confined within the prostate, - which by definition means at an early stage.
Only when fully confirmed, will such an announcement give new hope to hundreds of thousands of men annually, as well as to their wives and partners who love them.
Until further details of this study are verified and replicated, we can only hope that this report is telling it like it is! At the very least, we can begin to take renewed hope that scientists are at least on the way to making things better for us all.